Literature DB >> 26457751

A Multicenter Evaluation of Prolonged Empiric Antibiotic Therapy in Adult ICUs in the United States.

Zachariah Thomas1, Farooq Bandali, Jayashri Sankaranarayanan, Tom Reardon, Keith M Olsen.   

Abstract

OBJECTIVE: The purpose of this study is to determine the rate of prolonged empiric antibiotic therapy in adult ICUs in the United States. Our secondary objective is to examine the relationship between the prolonged empiric antibiotic therapy rate and certain ICU characteristics.
DESIGN: Multicenter, prospective, observational, 72-hour snapshot study.
SETTING: Sixty-seven ICUs from 32 hospitals in the United States. PATIENTS: Nine hundred ninety-eight patients admitted to the ICU between midnight on June 20, 2011, and June 21, 2011, were included in the study. INTERVENTION: None.
MEASUREMENTS AND MAIN RESULTS: Antibiotic orders were categorized as prophylactic, definitive, empiric, or prolonged empiric antibiotic therapy. Prolonged empiric antibiotic therapy was defined as empiric antibiotics that continued for at least 72 hours in the absence of adjudicated infection. Standard definitions from the Centers for Disease Control and Prevention were used to determine infection. Prolonged empiric antibiotic therapy rate was determined as the ratio of the total number of empiric antibiotics continued for at least 72 hours divided by the total number of empiric antibiotics. Univariate analysis of factors associated with the ICU prolonged empiric antibiotic therapy rate was conducted using Student t test. A total of 660 unique antibiotics were prescribed as empiric therapy to 364 patients. Of the empiric antibiotics, 333 of 660 (50%) were continued for at least 72 hours in instances where Centers for Disease Control and Prevention infection criteria were not met. Suspected pneumonia accounted for approximately 60% of empiric antibiotic use. The most frequently prescribed empiric antibiotics were vancomycin and piperacillin/tazobactam. ICUs that utilized invasive techniques for the diagnosis of ventilator-associated pneumonia had lower rates of prolonged empiric antibiotic therapy than those that did not, 45.1% versus 59.5% (p = 0.03). No other institutional factor was significantly associated with prolonged empiric antibiotic therapy rate.
CONCLUSIONS: Half of all empiric antibiotics ordered in critically ill patients are continued for at least 72 hours in absence of adjudicated infection. Additional studies are needed to confirm these findings and determine the risks and benefits of prolonged empiric therapy in the critically ill.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26457751     DOI: 10.1097/CCM.0000000000001294

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

1.  Prospective evaluating the appropriate use of piperacillin /tazobactam in cardiac center of a tertiary care hospital.

Authors:  Sanaa Saeed Mekdad; Leenah AlSayed
Journal:  J Cardiothorac Surg       Date:  2020-05-01       Impact factor: 1.637

2.  Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients.

Authors:  Marie-Charlotte Quinton; Sandra Bodeau; Loay Kontar; Yoann Zerbib; Julien Maizel; Michel Slama; Kamel Masmoudi; Anne-Sophie Lemaire-Hurtel; Youssef Bennis
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.

Authors:  H Woksepp; A Hällgren; S Borgström; F Kullberg; A Wimmerstedt; A Oscarsson; P Nordlund; M-L Lindholm; J Bonnedahl; L Brudin; B Carlsson; T Schön
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-04       Impact factor: 3.267

4.  Impact of Targeted Educational Interventions on Clostridium difficile Infection Treatment in Critically Ill Adults.

Authors:  Drayton A Hammond; Catherine A Hughes; Jacob T Painter; Rose E Pennick; Kshitij Chatterjee; Bradley Boye; Nikhil Meena
Journal:  Hosp Pharm       Date:  2016-12

5.  Factors Associated With Prolonged Antibiotic Use in the Setting of Suspected Pneumonia and Negative Bronchoalveolar Lavage Cultures.

Authors:  Jonathon D Pouliot; Marcus J Dortch; Gabrielle Givens; William Tidwell; Susan E Hamblin; Addison K May
Journal:  Hosp Pharm       Date:  2020-05-05

6.  Predictive modeling of bacterial infections and antibiotic therapy needs in critically ill adults.

Authors:  Garrett Eickelberg; L Nelson Sanchez-Pinto; Yuan Luo
Journal:  J Biomed Inform       Date:  2020-08-16       Impact factor: 6.317

Review 7.  Antibiotic therapy, supportive treatment and management of immunomodulation-inflammation response in community acquired pneumonia: review of recommendations.

Authors:  Marco Mantero; Paolo Tarsia; Andrea Gramegna; Sonia Henchi; Nicolò Vanoni; Marta Di Pasquale
Journal:  Multidiscip Respir Med       Date:  2017-10-05

8.  Evaluation of Meropenem Pharmacokinetics in an Experimental Acute Respiratory Distress Syndrome (ARDS) Model during Extracorporeal Membrane Oxygenation (ECMO) by Using a PenP β-Lactamase Biosensor.

Authors:  Max Andresen; Joaquin Araos; Kwok-Yin Wong; Yun-Chung Leung; Lok-Yan So; Wai-Ting Wong; Salvador Cabrera; Camila Silva; Leyla Alegria; Alejandro Bruhn; Dagoberto Soto
Journal:  Sensors (Basel)       Date:  2018-05-04       Impact factor: 3.576

9.  A Retrospective Analysis of Prolonged Empiric Antibiotic Therapy for Pneumonia Among Adult Neurocritical Care Patients.

Authors:  Ciera L Patzke; Michael J Armahizer; Neeraj Badjatia; Melissa Motta
Journal:  Neurohospitalist       Date:  2018-09-09

10.  Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers.

Authors:  Isabela Borges; Rafael Carneiro; Rafael Bergo; Larissa Martins; Enrico Colosimo; Carolina Oliveira; Saulo Saturnino; Marcus Vinícius Andrade; Cecilia Ravetti; Vandack Nobre
Journal:  Crit Care       Date:  2020-06-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.